

# Review of: "TROPION-Lung01 Results Indicate PFS Benefit with Datopotamab Deruxtecan over Docetaxel in Previously Treated Nonsquamous NSCLC: A Critique and Question"

Anders Mellemegaard<sup>1</sup>

<sup>1</sup> Nizam's Institute of Medical Sciences, Hyderabad, India

Potential competing interests: No potential competing interests to declare.

The paper reviews the recently published results from the Tropionlung01 study. As publications are often written with substantial input from the sponsor company, an independent review of data and presentation is very welcome.

The authors suggest a more objective presentation of data.

The paper starts off with copy-paste of news reels and the abstract.

The first table is confusing: an HR of 0.75 is explained as a 0.24% reduction in risk, while in fact it is a 24% reduction, etc., etc. I fail to see how the authors have arrived at these numbers, which are not factually correct.

The subsequent text is without any attempt to give the narrative a more balanced spin, and there is no discussion of the publication bias.

The manuscript looks very unfinished, more like a good idea that needs a lot of work to become a real paper. As it is, it does not contain anything of substance.